Subscribe
Subscribe
Picture of BioVox

BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is powered by Biovia: the health innovation cluster for Flanders.
Picture of BioVox

BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is powered by Biovia: the health innovation cluster for Flanders.

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference

Belgium again attends the BIO International Convention 2017 with a stunning 74 companies and organizations and 135 delegates on one of the most vibrant pavilions at the conference. The Belgian delegation comes together in one of the most vibrant pavilions at the conference. 

Ablynx appoints Markus Ewert as Chief Business Officer

Biocartis launches CE-marked IVD test for lung cancer

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Genetic engineering specialist Delphi Genetics announced that it has received the certificate of Good Manufacturing Practice (GMP) for plasmid DNA production. The GMP productions will be realized in clean rooms located in Delphi Genetics’ own facilities. Furthermore, the GMP facilities will benefit from the company's 'Antibiotic Free" Technology.

IDO 1: a promising new target for immunotherapy

Immunotherapy: a paradigm shift in cancer treatment

An excerpt from the BioVox White paper on Cancer Immunotherapy.

KWS and Bayer grant first license for herbicide-tolerant sugarbeet to SESVanderHave

KWS SAAT SE and Bayer AG have given access to a long-term license for their new CONVISO®SMART cultivation system for sugarbeet to the Belgian sugarbeet seed breeding company SESVanderHave. The technology is based on the breeding of sugarbeet varieties that are tolerant to herbicides in the ALS inhibitor class with broad-spectrum weed control.

Reinforcing veins with computer simulations

Each year, more than two million patients worldwide undergo a procedure called coronary artery bypass grafting (CABG). CABG is used to treat blocked arteries and restore normal blood flow to the heart. It involves grafting a blood vessel — typically taken from the leg — around the diseased area, reestablishing blood flow to the heart tissue. However, veins used for CABG offer an inadequately durable solution to coronary artery disease, and the long-term outlook is not promising. Within 18 months, 25 percent of implanted veins fail. After 5 years, that failure rate increases to 40 percent. Angioshield, a novel type of external stent designed through ANSYS' computer simulations, offers a solution to this problem.

Diagnosing rare genetic conditions within minutes

Sylvie Janssen in Manhattan – Belgian scientist living abroad

MDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device for prostate cancer

MDx Health has launched its new prostate cancer test. SelectMDx is designed to detect prostate cancer in urine samples, avoiding painful prostate biopsies when cancer is suspected.

Biocartis collaborates with MRC Technology in development of breast cancer liquid biopsy test

Together with MRC Technology, Biocartis has announced a collaboration for the development of a liquid biopsy test for hormone treatment-resistant breast cancer.

Scientists give tumor-fighting cells a boost in battling bone marrow cancer

Cochlear acquires exclusive licence to Artificial Intelligence assistant

PDC*Line Pharma awarded by board of international cancer experts

At the 8th edition of MATWIN’s annual international board meeting PDC*Line Pharma was awarded with the prize of Most Promising Project in the start-up category.